Citations

Clear

904 citation(s) found for "Gordon, S".

A National Survey of Transplant Surgeons and Nephrologists on Implementing Apolipoprotein L1 ( APOL1 ) Genetic Testing Into Clinical Practice
Gordon, Elisa J. , Wicklund, Catherine , Lee, Jungwha , Sharp, Richard R. , Sharp, Richard R , Friedewald, John J.

Mayo Clinic

Progress in Transplantation | December 13, 2018 | Volume: 29 | Issue: 1 | Pages: 26-35

10.1177/1526924818817048 | PMID 30541404 Get It

Introduction: There is debate over whether Apolipoprotein L1 (APOL1) gene risk variants contribute to African American (AA) live donors’ (LD) increased risk of kidney failure. Little is known about factors influencing physicians’ integration of APOL1 genetic testing of AA LDs into donor evaluation. Design: We conducted a cross-sectional survey, informed by Roger’s Diffusion of Innovations theory, among nephrology and surgeon members of the American Society of Nephrology, American Society of Transplantation, and American Society of Transplant Surgeons about their practices of and attitudes about APOL1 genetic testing of AA potential LDs. Descriptive statistics and bivariate analyses were performed. Results: Of 383 completed surveys, most physicians believed that APOL1 testing can help AA LDs make more informed donation decisions (87%), and the addition of APOL1 testing offers better clinical information about AA LD’s eligibility for donation than existing evaluation approaches (74%). Among respondents who evaluate LDs (n = 345), 63% would definitely or probably begin or continue using APOL1 testing in the next year, however, few use APOL1 testing routinely (4%) or on a case-by-case basis (14%). Most did not know the right clinical scenario to order APOL1 testing (59%), but would use educational materials to counsel AA LDs about APOL1 testing (97%). Discussion: Although physicians were highly supportive of APOL1 genetic testing for AA LDs, few physicians use APOL1 testing. As more physicians intend to use APOL1 testing, an ethical framework and clinical decision support are needed presently to assist clinicians in clarifying the proper indication of APOL1 genetic testing.
RUNX1‐dependent mechanisms in biological control and dysregulation in cancer
Hong, Deli , Fritz, Andrew J. , Gordon, Jonathan A. R., Tracy, Kirsten M. , Frietze, Seth , Carr, Frances E. , Nickerson, Jeffrey A. , Wijnen, André J. van , Imbalzano, Anthony N. , Zaidi, Sayyed K. , Lian, Jane B. , Stein, Janet L. , Tracy, Kirsten M , van Wijnen, Andre J , Stein, Gary S , Tye, Coralee E. , Boyd, Joseph R. , Stein, Gary S.

Mayo Clinic

Journal of Cellular Physiology | December 5, 2018 | Volume: 234 | Issue: 6 | Pages: 8597-8609

10.1002/jcp.27841 | PMID 30515788 Get It

AbstractThe RUNX1 transcription factor has recently been shown to be obligatory for normal development. RUNX1 controls the expression of genes essential for proper development in many cell lineages and tissues including blood, bone, cartilage, hair follicles, and mammary glands. Compromised RUNX1 regulation is associated with many cancers. In this review, we highlight evidence for RUNX1 control in both invertebrate and mammalian development and recent novel findings of perturbed RUNX1 control in breast cancer that has implications for other solid tumors. As RUNX1 is essential for definitive hematopoiesis, RUNX1 mutations in hematopoietic lineage cells have been implicated in the etiology of several leukemias. Studies of solid tumors have revealed a context‐dependent function for RUNX1 either as an oncogene or a tumor suppressor. These RUNX1 functions have been reported for breast, prostate, lung, and skin cancers that are related to cancer subtypes and different stages of tumor development. Growing evidence suggests that RUNX1 suppresses aggressiveness in most breast cancer subtypes particularly in the early stage of tumorigenesis. Several studies have identified RUNX1 suppression of the breast cancer epithelial‐to‐mesenchymal transition. Most recently, RUNX1 repression of cancer stem cells and tumorsphere formation was reported for breast cancer. It is anticipated that these new discoveries of the context‐dependent diversity of RUNX1 functions will lead to innovative therapeutic strategies for the intervention of cancer and other abnormalities of normal tissues.
Low income as a determinant of exercise capacity in COPD
Porta, Ana Sofia , Lam, Nyanjok, Novotny, Paul J. , Benzo, Roberto , Bernard, Gordon R. , Hoffman, Jeanne M. , Kaplan, Robert C. , Novotny, Paul, Lam, Nyanjok M

Mayo Clinic

Chronic Respiratory Disease | November 18, 2018 | Volume: 16 | Issue: No issue available | Pages: No page available

10.1177/1479972318809491 | PMID 30449156 Get It

Exercise capacity (EC) is a critical outcome in chronic obstructive lung disease (chronic obstructive pulmonary disease (COPD)). It measures the impact of the disease and the effect of specific interventions like pulmonary rehabilitation (PR). EC determines COPD prognosis and is associated with health-care utilization and quality of life. Field walking tests and cardiopulmonary exercise test (CPET) are two ways to measure EC. The 6-minute walking test (6MWT) is the commonest and easiest field test. CPET has the advantage of assessing maximal aerobic capacity. Determinants of EC include age, gender, breathlessness, and lung function. Previous research suggests that socioeconomic status (SES), a meaningful factor in COPD, may also be associated with EC. However, those findings have not been replicated. We aimed to determine whether SES is an independent factor associated with EC in COPD. For this analysis, we used the National Emphysema Treatment Trial (NETT) database. NETT was a multicenter clinical trial where severe COPD patients were randomized to lung volume reduction surgery or medical therapy. Measures used were taken at baseline, postrehabilitation. Patients self-reported their income and were divided in two groups whether it was less or above US$30,000. Patients with a lower income had worse results in 6MWT ( p < 0.0001). We found an independent association between income and the 6MWT in patients with severe COPD after adjusting for age, gender, lung function, dyspnea, and living conditions ( p < 0.0007). One previous publication stated the relationship between income and EC. Our research confirms and extends previous publications associating EC with income by studying a large and well characterized cohort of severe COPD patients, also addressing EC by two different methods (maximal watts and 6MWT). Our results highlight the importance of addressing social determinants of health such as income when assessing COPD patients.
Propeptide glycosylation and galectin‐3 binding decrease proteolytic activation of human proMMP‐9/progelatinase B
Boon, Lise , Ugarte-Berzal, Estefanía , Martens, Erik , Vandooren, Jennifer , Rybakin, Vasily , Colau, Didier , Bruggen, Pierre van der , Stöcker, Walter , Becker‐Pauly, Christoph , Jaeken, Jaak , Proost, Paul , Opdenakker, Ghislain , Proost, Paul , Opdenakker, Ghislain , Gordón‐Alonso, Mónica , Witters, Peter , Morava, Éva

Mayo Clinic

The FEBS Journal | November 13, 2018 | Volume: 286 | Issue: 5 | Pages: 930-945

10.1111/febs.14698 | PMID 30422384 Get It

Matrix metalloproteinases (MMPs) are secreted as proenzymes, containing propeptides that interact with the catalytic zinc, thereby controlling MMP activation. The MMP‐9 propeptide is unique in the MMP family because of its post‐translational modification with an N‐linked oligosaccharide. ProMMP‐9 activation by MMP‐3 occurs stepwise by cleavage of the propeptide in an aminoterminal (pro‐AT) and carboxyterminal (pro‐CT) peptide. We chemically synthesized aglycosyl pro‐AT and pro‐CT and purified recombinant glycosylated pro‐ATSf−9. First, we report new cleavage sites in the MMP‐9 propeptide by MMP‐3 and neutrophil elastase. Additionally, we demonstrated with the use of western blot analysis a higher resistance of glycosylated versus aglycosyl pro‐AT against proteolysis by MMP‐3, MMP‐9, meprin α, neutrophil elastase and by protease‐rich synovial fluids from rheumatoid arthritis patients. Moreover, we investigated the effect of glycosylation on proteolytic activation of human proMMP‐9 with the use of zymography and dye‐quenched gelatin cleavage analysis. Compared to recombinant Sf‐9 proMMP‐9 glycoforms, larger oligosaccharides of human neutrophil proMMP‐9 increased resistance against proteolytic activation. Additionally, proMMP‐9 from Congenital Disorder of Glycosylation patients, compared to healthy controls, showed a higher activation rate by MMP‐3. Finally, we demonstrated that glycan‐galectin‐3 interactions reduced proMMP‐9 activation. In conclusion, modification of MMP‐9 propeptide glycosylation is a fine‐tuning mechanism and co‐determines the specific activity of MMP‐9 in physiology and pathology.EnzymesMMP‐9 EC 3.4.24.35, MMP‐3 EC 3.4.24.17, meprin α EC 3.4.24.18, neutrophil elastase EC 3.4.21.37, trypsin EC 3.4.21.4 and PNGase F EC 3.5.1.52.
Revising Diagnostic and Statistical Manual of Mental Disorders , Fifth Edition, criteria for the bipolar disorders: Phase I of the AREDOC project
Tavella, Gabriela , Berk, Michael , Grunze, Heinz , Deckersbach, Thilo , Dünner, David L., Amsterdam, Jay D., Ketter, Terence A. , Yatham, Lakshmi N. , Kessing, Lars Vedel , Bassett, Darryl, Fountoulakis, Kostas N, Duffy, Anne , Alda, Martin , Sharma, Verinder , Singh, Manpreet K. , Hájek, Tomáš , Boyce, Philip , Frey, Benício N. , Castle, David , Young, Allan H. , Vieta, Eduard , Swartz, Holly A. , Schaffer, Ayal , Murray, Greg , Bayes, Adam , Lam, Raymond W. , Post, Robert M, Ostacher, Michael J. , Lafer, Beny , Cleare, Anthony J. , O’Donovan, Claire , Ortiz, Abigail, Henry, Chantal , Kanba, Shigenobu, Rosenblat, Joshua D. , Parikh, Sagar V. , Bond, David J. , Goldberg, Joseph F. , Orum, Margo, Osser, David N. , Frye, Mark A. , Manicavasagar, Vijaya , Carlson, Gabrielle A. , Malhi, Gin S. , Fountoulakis, Konstantinos Ν. , Vieta, E , Grunze, Heinz , Bond, David J , Hajek, Tomas , Alda, Martin , Fountoulakis, Konstantinos N , Yatham, Lakshmi N , Young, Allan H , Cleare, Anthony J , Berk, Michael , Ortiz, Abigail , Parker, Gordon Barraclough , MacQUEEN, GLENDA M. , Sajatovic, Martha , Zimmerman, Mark A. , Fountoulakis, Kostas N, Calkin, Cynthia , Anand, Amit , Rybakowski, Janusz K , Bora, Emre , Post, Robert M, Burdick, Katherine E. , Grunebaum, Michael F. , Frangou, Sophia , McIntyre, Roger S. , Fagiolini, Andrea , Swartz, Holly A , Kessing, L V , Malhi, Gin S , Ostacher, Michael J

Mayo Clinic

Australian & New Zealand Journal of Psychiatry | October 31, 2018 | Volume: 52 | Issue: 12 | Pages: 1173-1182

10.1177/0004867418808382 | PMID 30378461 Get It

Objective: To derive new criteria sets for defining manic and hypomanic episodes (and thus for defining the bipolar I and II disorders), an international Task Force was assembled and termed AREDOC reflecting its role of Assessment, Revision and Evaluation of DSM and other Operational Criteria. This paper reports on the first phase of its deliberations and interim criteria recommendations. Method: The first stage of the process consisted of reviewing Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, and recent International Classification of Diseases criteria, identifying their limitations and generating modified criteria sets for further in-depth consideration. Task Force members responded to recommendations for modifying criteria and from these the most problematic issues were identified. Results: Principal issues focussed on by Task Force members were how best to differentiate mania and hypomania, how to judge ‘impairment’ (both in and of itself and allowing that functioning may sometimes improve during hypomanic episodes) and concern that rejecting some criteria (e.g. an imposed duration period) might risk false-positive diagnoses of the bipolar disorders. Conclusion: This first-stage report summarises the clinical opinions of international experts in the diagnosis and management of the bipolar disorders, allowing readers to contemplate diagnostic parameters that may influence their clinical decisions. The findings meaningfully inform subsequent Task Force stages (involving a further commentary stage followed by an empirical study) that are expected to generate improved symptom criteria for diagnosing the bipolar I and II disorders with greater precision and to clarify whether they differ dimensionally or categorically.
O3‐13‐03: THE RELATIONSHIP BETWEEN TAU PET AND OTHER AD BIOMARKERS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE
Christensen, Jon, Dincer, Aylin , Keefe, Sarah , Wang, Guoqiao , Raichle, Marcus E. , Koeppe, Bob, Network, Dominantly Inherited Alzheimer's, Gordon, Brian A. , Blazey, Tyler , Flores, Shaney , McDade, Eric , Jack, Clifford R. , Morris, John C. , Bateman, Randall J. , Benzinger, Tammie L.S. , Network, Dominantly Inherited Alzheimer's

Mayo Clinic

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_19 | Pages: No page available

10.1016/j.jalz.2018.06.2845 Get It

IC‐P‐204: THE RELATIONSHIP BETWEEN TAU PET AND OTHER AD BIOMARKERS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE
Christensen, Jon, Dincer, Aylin , Keefe, Sarah , Wang, Guoqiao , Raichle, Marcus E. , Koeppe, Bob, Network, Dominantly Inherited Alzheimer's, Gordon, Brian A. , Blazey, Tyler , Flores, Shaney , McDade, Eric , Jack, Clifford R. , Morris, John C. , Bateman, Randall J. , Benzinger, Tammie L.S. , Network, Dominantly Inherited Alzheimer's

Mayo Clinic

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_3 | Pages: No page available

10.1016/j.jalz.2018.06.2271 Get It

P2‐651: A CONSENSUS AROUND GLOBAL RESEARCH PRIORITIES FOR COMMUNITY‐BASED CARE FROM A STRATEGIC CONVENING MODEL IN SALZBURG, AUSTRIA
Lunde, Angela , Johnston, Claiborne S., Roger, Véronique L. , Gordon, Kate , Nomidou, Aikaterini , Little, A. N., Agbaje, Babatunde, Mastery, Olivia, Hu, William T. , Gordon, Kate, Kayano, Ryoma

Mayo Clinic

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_18 | Pages: No page available

10.1016/j.jalz.2018.06.1347 Get It

Utility of perfusion PET measures to assess neuronal injury in Alzheimer's disease
Joseph‐Mathurin, Nelly , Jasielec, Mateusz S., Vlassenko, Andrei G. , Gordon, Brian A. , Hornbeck, Russ C. , Cash, Lisa, Veale, Thomas , Cash, David M. , Buckles, Virginia, Cairns, Nigel J. , Goate, Alison , Karch, Celeste M. , Klunk, William E. , Marcus, Daniel S. , Mayeux, Richard , Noble, James M. , Ringman, John M. , Xiong, Chengjie , Morris, John C. , Bateman, Randall J. , Network, Dominantly Inherited Alzheimer, Gordon, Brian A , Bateman, Randall J , Joseph-Mathurin, Nelly , Karch, Celeste M , Morris, John C , Cash, David M , Su, Yi , Blazey, Tyler , Friedrichsen, Karl A. , Ances, Beau M. , Brickman, Adam M. , Cruchaga, Carlos , Jack, Clifford R. , Koeppe, Robert A. , McDade, Eric , Saykin, Andrew J. , Thompson, Paul M. , Benzinger, Tammie L.S. , Network, Dominantly Inherited Alzheimer, Goate, Alison M , Noble, James M

Mayo Clinic

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | September 27, 2018 | Volume: 10 | Issue: 1 | Pages: 669-677

10.1016/j.dadm.2018.08.012 | PMID 30417072 Get It

AbstractIntroduction18F‐fluorodeoxyglucose (FDG) positron emission tomography (PET) is commonly used to estimate neuronal injury in Alzheimer's disease (AD). Here, we evaluate the utility of dynamic PET measures of perfusion using 11C‐Pittsburgh compound B (PiB) to estimate neuronal injury in comparison to FDG PET.MethodsFDG, early frames of PiB images, and relative PiB delivery rate constants (PiB‐R1) were obtained from 110 participants from the Dominantly Inherited Alzheimer Network. Voxelwise, regional cross‐sectional, and longitudinal analyses were done to evaluate the correlation between images and estimate the relationship of the imaging biomarkers with estimated time to disease progression based on family history.ResultsMetabolism and perfusion images were spatially correlated. Regional PiB‐R1 values and FDG, but not early frames of PiB images, significantly decreased in the mutation carriers with estimated year to onset and with increasing dementia severity.DiscussionHypometabolism estimated by PiB‐R1 may provide a measure of brain perfusion without increasing radiation exposure.